

Protalix BioTherapeutics, Inc.  
Form 8-K  
October 26, 2011

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

\_\_\_\_\_  
FORM 8-K  
\_\_\_\_\_

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 26, 2011

\_\_\_\_\_  
Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida  
(State or other jurisdiction  
of incorporation)

001-33357  
(Commission File Number)

65-0643773  
(IRS Employer  
Identification No.)

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel  
(Address of principal executive offices)

20100  
(Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01. Regulation FD Disclosure

On October 26, 2011, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that senior management will present at four upcoming conferences:

Ernst & Young Journey 2011 Conference

Wednesday, November 2, 2011 at 2:45 PM IDT

Topic: The Pfizer-Protalix Gaucher Collaboration – The Partners’ Point of View

Dr. David Aviezer, President & CEO

Hilton Hotel, Tel-Aviv, Israel

PDA-Parenteral Drug Association / FDA-Food and Drug Administration:

Adventitious Agents and Novel Cell Substrates Conference

Thursday, November 3, 2011 at 1:15-3:15 PM ET

Topic: Potential Safety and Quality Issues Related to Plants and Plant-Based Products

Dr. Yoseph Shaaltiel, Executive Vice President, R&D

Hilton Washington DC / Rockville Hotel & Executive Meeting Center, Rockville, MD, USA

Lazard Capital Markets 8th Annual Healthcare Conference

Wednesday, November 16, 2011 at 1:30 PM ET

Topic: Corporate Presentation

Mr. Yossi Maimon, CFO

Pierre Hotel, New York, NY, USA

A webcast of this presentation will be available at [www.protalix.com](http://www.protalix.com) on the event calendar page. A replay will be archived and available after the conference for 30 days.

World Orphan Drug Congress

Thursday, December 1, 2011 at 10:10 AM CEST

Topic: Regulatory Expectations and Clinical Strategy for Treating Fabry Disease

Dr. David Aviezer, President & CEO

Crowne Plaza Hotel, Geneva, Switzerland

A copy of the press release is furnished as Exhibit 99.1.

The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d)

Exhibits

99.1

Press release dated October 26, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: October 26, 2011

By: /s/ Yossi Maimon  
Name: Yossi Maimon  
Title: Chief Financial Officer